Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of MPD-1 in Patients With Advanced Solid Tumor

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 10, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions

CancerSolid Tumor CancerBiomarkers

Interventions

DRUG

MPD-1

It is a prodrug that uses Doxorubicin to target KRAS mutant/ PTEN loss advanced cancer.

Trial Locations (1)

RECRUITING

Asan Medical Center, Seoul

All Listed Sponsors

lead

Pharosgen Co.,Ltd

INDUSTRY